Rivaroxaban in Type 2 Myocardial Infarctions (R2MI)
-
- STATUS
- Not Recruiting
-
- participants needed
- 8
-
- sponsor
- University of Alberta
Summary
This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.
Description
This trial is an investigator-initiated prospective, single-center, placebo-controlled, double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice daily) for 90-days following a type 2 myocardial infarction. The primary feasibility outcome is time to recruitment of 100 participants, stratified by sex.
Details
| Condition | Type II Myocardial Infarction |
|---|---|
| Age | 45years or above |
| Clinical Study Identifier | NCT04838808 |
| Sponsor | University of Alberta |
| Last Modified on | 10 November 2025 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.